Key result
Higher percent atheroma volume, layered plaque, and cholesterol crystals predict intraplaque hemorrhage in stable CAD.
Why the study?
Detailed plaque features exhibiting residual intraplaque haemorrhage despite statin therapy in stable CAD patients remain unknown.
Observational (n=121)
In statin-treated patients with stable CAD, intraplaque haemorrhage remains prevalent and can be identified in vivo by a clustering of specific plaque characteristics including percent atheroma volume, low-intensity area, and cholesterol crystals.
Residual intraplaque haemorrhage features persist despite statins in CAD; hypothesis-generating and leaves open need for adjunctive therapies.
Aims Plaque-to-myocardium ratio (PMR) ≥1.0 on cardiac magnetic resonance (CMR) has been histologically validated to correspond to intraplaque haemorrhage. Despite the use of statins, PMR values remained above 1.0. Detailed plaque features exhibiting residual intraplaque haemorrhage despite statin therapy remains unknown. Objectives To characterize features of plaques exhibiting PMR ≥1.0 in statin-treated patients with CAD. Methods and results Target (n = 161) and non-target (n = 142) lesions in 121 statin-treated stable CAD patients were imaged by CMR, near-infrared spectroscopy (NIRS)/intravascular ultrasound (IVUS), and optical coherence tomography (OCT) (NCT04864171). NIRS/IVUS-derived measures, OCT-derived low-intensity area without attenuation (LIA), and the arc of LIA were compared between lesions with and without PMR ≥1.0. PMR ≥1.0 was observed at 34.2% and 19.7% of target and non-target lesions, respectively. Target lesions with PMR ≥1.0 presented greater percent atheroma volume (PAV) and higher maxLCBI4mm with greater frequencies of layered plaques, cholesterol crystals, and LIA (P < 0.001 for all). Multivariable analysis demonstrated PAV [odds ratio (OR) = 1.05, 95% confidence interval (CI) = 1.01–1.09, P = 0.006], layered plaque (OR = 3.17, 95% CI = 1.03–9.78, P = 0.045), cholesterol crystal (OR = 3.79, 95% CI = 1.30–11.03, P = 0.015), and LIA arc (OR = 1.04, 95% CI = 1.01–1.06, P < 0.001) but not maxLCBI4mm (OR = 1.001, 95% CI = 0.999–1.003, P = 0.227) as predictors of PMR ≥1.0 at target lesions. Notably, the frequency of PMR ≥1.0 increased to 92.0% in target lesions exhibiting all plaque features (PAV ≥ 62.1%, layered plaque, cholesterol crystal, LIA arc ≥18.0°). In non-target lesions, PAV ≥ 53.1%, cholesterol crystal and LIA arc ≥16.5° predicted PMR ≥1.0. A clustering of these features elevated the frequency of PMR ≥1.0 (P < 0.001). Conclusion Statin-treated patients still harboured PMR ≥1.0. PAV, LIA, and cholesterol crystal predicted PMR ≥1.0 at both target and non-target lesions. Clustering of these plaque characteristics may enable to better identify intraplaque haemorrhage in vivo.
No takes yet. Share an insight, caveat, or question.
Nakata et al. (2026) conducted an observational in stable coronary artery disease (n=121). Percent atheroma volume (PAV) was evaluated on Plaque-to-myocardium ratio (PMR) ≥1.0 at target lesions (OR 1.05, 95% CI 1.01-1.09, p=0.006). Percent atheroma volume (OR 1.05; 95% CI 1.01-1.09), layered plaque, and cholesterol crystals independently predicted intraplaque haemorrhage (PMR ≥1.0) in statin-treated patients with stable CAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: